FDA Approves First Therapy for Allergic Fungal Rhinosinusitis - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves First Therapy for Allergic Fungal Rhinosinusitis

Patients with allergic fungal rhinosinusitis now have a targeted biologic option.

  • By

  • Kathryn Wighton

  • February 25, 2026

  • 2 min

Share

Objective:

To announce the FDA approval of dupilumab for treating allergic fungal rhinosinusitis (AFRS) in patients aged 6 years and older.

Approach:
    Key Findings:
    • Dupilumab improved sinus opacification compared to placebo.
    • Treatment reduced the need for systemic corticosteroids and sinus surgery.
    • Dupilumab reduced sinus bone erosion, a complication specific to AFRS.
    • The safety profile was consistent with previous findings in chronic rhinosinusitis with nasal polyps.
    Interpretation:

    Dupilumab is the first FDA-approved therapy specifically for AFRS, demonstrating significant clinical benefits and a favorable safety profile.

    Limitations:
    • Pediatric efficacy was extrapolated from adult data.
    • Safety data in pediatric patients were derived from studies in other indications.
    Conclusion:

    Dupilumab represents a significant advancement in the treatment of allergic fungal rhinosinusitis, offering new hope for affected patients.

    Sources:

Original Source(s)

FDA Approves First Therapy for Allergic Fungal Rhinosinusitis

  • by Kathryn Wighton

  • February 25, 2026

Related Content

Top 10 evidence-based essentials in pediatrics

A structured framework of guidelines, trials, therapies, and clinical tools used in pediatric practice.

Outdoor artificial nighttime light may raise childhood myopia risk

Higher exposure was associated with new-onset myopia over 3 years, with risk increasing sharply at higher nighttime light levels.

Enterovirus diversity may limit treatment advances

Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.